[Press Release] Lucence advances Asian genomics with clinical-grade genome sequencing for Singapore’s precision medicine programme

Genomic-Sequencing-Blog-Feature-1.png

FOR IMMEDIATE RELEASE

  • Lucence brings together clinical genomics expertise with QIAGEN and Ultima  Genomics, as Phase III expands to nearly 1 in 10 people in Singapore from 2027

SINGAPORE – Lucence – 3 November 2026 – Lucence is bringing its clinical genomics expertise to Singapore’s  next phase of precision medicine, supporting a national effort to build deeper understanding of  Asian genetic diversity and how it could shape more targeted approaches to health and disease. 

Selected as one of two sequencing providers for SG-INSIGHT – a cohort under Phase III of  Singapore’s National Precision Medicine (NPM) programme – this phase will involve approximately 450,000 residents, or nearly one in 10 Singapore residents. This marks a  significant expansion in the scale and scope of Singapore’s precision medicine effort. 

Much of today’s genomic knowledge has historically been developed from populations of  predominantly European ancestry. Yet genetic differences across populations can influence  disease risk and response to medicines, underscoring the importance of generating genomic  evidence that better represents Asian populations. 

Dr Tan Min-Han, Founding CEO of the Lucence Group, said: “Genetics is not one-size-fits-all.  For precision medicine to work for people in Asia, we need evidence from Asian populations.  Singapore offers a particularly valuable setting for this work. Our Chinese, Malay and Indian  populations bring significant genetic diversity together within a single healthcare and research  ecosystem, alongside longitudinal health information and established research infrastructure. 

“The promise of genomics is that prevention can become much more personal. If we can better  understand who may be pre-disposed to diseases such as cancer or cardiovascular and  metabolic diseases, we can start thinking about prevention and healthcare in a much more  individualised way.” 

Building Asian genomic capability at national scale 

By studying genetic information alongside lifestyle and environmental factors in real-world clinical  settings, the programme aims to deepen understanding of disease progression and treatment  response, and build the evidence needed to support the safe and effective rollout of genetic  screening within Singapore’s public healthcare system. 

Scale will be important to generating that evidence. Larger and more representative populations  allow researchers to identify genetic associations that may be difficult to detect in smaller studies  and build a more detailed picture of how genetic variation may influence health across different  populations. 

NPM Phase III builds on earlier phases that have progressively expanded Singapore’s genomic  knowledge. Phase I sequenced 10,000 Singaporeans across the Chinese, Malay and Indian  populations, while Phase II expanded the programme to approximately 100,000 residents.  Phase III will extend this further to approximately 450,000 residents. 

Unlike Phase II, which focused on healthy individuals, Phase III will include patients across a  wide spectrum of health conditions from Singapore’s three healthcare clusters: NHG Health, National University Health System (NUHS) and SingHealth. Nearly one in 10 people receiving  medical treatment and healthcare services may encounter the study through their routine care. 

Bridging local expertise and global technology 

Studying genomes at population scale can reveal patterns and associations that smaller studies  may not capture. Delivering genomic information at this scale requires expertise across the entire  sequencing workflow. To deliver SG-INSIGHT, Lucence is working with global leader in Sample to  Insight solutions, QIAGEN, and Ultima Genomics. 

The collaboration brings together complementary strengths across the sequencing workflow,  combining QIAGEN’s sample preparation technologies and Ultima Genomics’ sequencing and  bioinformatics capabilities.  

Lucence will integrate these technologies within its clinical laboratory operations and oversee the  end-to-end processes required to deliver the sequencing services. This includes providing the  laboratory infrastructure, workflows and scientific personnel, as well as the regulatory and  operational expertise required to generate the data in line with the programme’s requirements. 

Eric Goh, Head of Commercial Operations, Southeast Asia at QIAGEN said: “We are thrilled  to partner with Lucence and Ultima Genomics in supporting SG-INSIGHT, the flagship cohort for  Phase III of Singapore’s National Precision Medicine programme. Deploying our flagship  QIAsprint Connect and QIAseq FX Library Kit in this national scale initiative highlights QIAGEN’s  commitment to providing reliable, automated and high-throughput sample to insight solutions that  power next-generation population genomics.” 

Gilad Almogy, CEO of Ultima Genomics said: “We are proud to support such an important  national-scale clinical whole genome sequencing initiative and to partner with industry leaders  Lucence and QIAGEN to enable clinical-grade, high-throughput germline whole genome  sequencing. The selection of Ultima’s sequencing technology reflects significant recent  advancements to our platform, including the launch of our second-generation UG200 and Solaris  2.0 chemistry, which are expanding the potential for germline applications at scale. 

“We look forward to partnering with Lucence and QIAGEN to support the PRECISE  initiative. Looking ahead, Ultima continues to advance its sequencing and analysis capabilities to  support clinical whole genome sequencing at population scale, including pangenome-aware  analysis and paired-end sequencing, with both expected to be available by year-end 2026.” 

Translating genomic expertise into impact 

Lucence brings a decade of genomic sequencing expertise to SG-INSIGHT. Over the years, it  has applied these capabilities across precision medicine, with a strong track record in cancer genomics. The Group’s proprietary next-generation sequencing technologies for genomic profiling are supported by its CLIA-licensed and CAP-accredited laboratory in Singapore. 

Its proprietary AmpliMARK™ next-generation sequencing technology underpins its liquid biopsy  capabilities, enabling the analysis of genetic information from circulating tumour DNA and RNA1. More recently, Lucence expanded into increasingly comprehensive approaches to genomic  analysis. In March 2026, it embarked on a S$6 million research collaboration with A*STAR’s Diagnostics Development Hub and the National Cancer Centre Singapore to develop a clinical grade cancer profiling test using whole exome and whole transcriptome sequencing, together with  artificial intelligence. 

Dr Tan concluded: “My vision is for Singapore to help define the next generation of genomics,  discovering how our differences influence cancer and diseases of ageing, and translating what  we learn here into better precision health for Asia and the world.”

Media Contacts 

Melissa Chew
Marketing & Communications
Lucence
[email protected]  

Yiting Foo
Eleven Pte Ltd
[email protected]


1ctDNA refers to circulating tumour DNA, which are small fragments of genetic material shed by cancer cells into body fluids  such as blood or urine. ctRNA refers to circulating tumour RNA, which can provide additional information about cancer-related  activity and signals. Looking at DNA and RNA gives clinicians a broader view of cancer signals: DNA shows cancer-related  mutations, while RNA adds information on cancer-related activity.

About Lucence 

Lucence is a precision health company committed to accelerating the world towards people living  longer and healthier lives, enabled by earlier and non-invasive detection of markers associated  with cancer and other aging diseases. Its ultra-sensitive liquid biopsy tests are based on  proprietary AmpliMark™ sequencing technology, designed to detect cancer-related genetic  alterations with high sensitivity and specificity. Headquartered in Palo Alto, California, and  Singapore, Lucence provides testing services through CLIA-certified and CAP-accredited  laboratories. 

About PRECISE 

Precision Health Research, Singapore (PRECISE) is the national central entity coordinating  Singapore’s multi-phase National Precision Medicine (NPM) programme. Established to drive a  whole-of-Singapore effort, PRECISE works with research, clinical and industry partners to  generate insights into Asian genomics and translate these into better health outcomes and  economic opportunities.  

PRECISE is a programme of the Consortium for Clinical Research and Innovation, Singapore.  NPM Phase II is supported by the National Research Foundation, Singapore (NRF) under the  White Space funding (MOH-000588 and MOH-001264) and administered by the Singapore  Ministry of Health (MOH) through the National Medical Research Council (NMRC) Office, MOH  Holdings Pte Ltd. NPM Phase III is supported by the Singapore MOH through the NMRC Office,  MOH Holdings Pte Ltd under the NMRC NPM Phase III Funding Initiative (MOH-001734). 

www.npm.sg

References:

  1. Wong, Eleanor, Nicolas Bertin, Maxime Hebrard, Roberto Tirado-Magallanes, Claire  Bellis, Weng Khong Lim, Chee Yong Chua, et al. “The Singapore National Precision  Medicine Strategy.” Nature Genetics 55, no. 2 (January 19, 2023): 178–86.  https://doi.org/10.1038/s41588-022-01274-x.  
  2. Chan, Sock Hoai, Yasmin Bylstra, Jing Xian Teo, Jyn Ling Kuan, Nicolas Bertin, Mar  Gonzalez-Porta, Maxime Hebrard, et al. “Analysis of Clinically Relevant Variants from  Ancestrally Diverse Asian Genomes.” Nature News, November 5, 2022.  
    https://www.nature.com/articles/s41467-022-34116-9.  
  3. Malik, Ashar J., Dimitar Kenanov, Cheng-Shoong Chong, Mert Burak Ozturk, Qiqi Wang,  Hong-Yun Chang, Maxime Hebrard, et al. “Genomic Landscape of Drug Binding and  Pharmacogenetic Variation across Diverse Populations Using Snpdrug3d.” Nature  Communications 17, no. 1 (June 9, 2026). https://doi.org/10.1038/s41467-026-73816-4.  
  4. Seow, Shih Wee, Theresia Mina, Maxime Hebrard, Nilanjana Sadhu, Claire Bellis, Bitong  Clarabelle Lin, Pritesh Jain, et al. “Translating Genomic Data into Healthcare Practice  with the Singapore National Precision Medicine Program.” Nature Genetics 58, no. 8 (July  29, 2026): 1760–72. https://doi.org/10.1038/s41588-026-02687-8.
scroll to top